Hospital of Prato

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani意大利5
2. University of Pisa意大利2
3. University of Molise意大利1
4. Azienda Usl Toscana Centro意大利1
5. University of Catania意大利1
6. University of Florence意大利1
7. Nuovo Ospedale San Giovanni di Dio意大利1
8. University of Udine意大利1

按月发文

逐年被引

最新文献

1. 1
   Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsExpert Opinion on Drug Safety20217
2. 2
   Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus KinasesExpert Opinion on Drug Safety202044
3. 3
   The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritisExpert Opinion on Drug Safety201911
4. 4
   Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practiceExpert Opinion on Drug Safety201964
5. 5
   Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variablesTherapeutics and Clinical Risk Management20184
6. 6
   IntroductionExpert Opinion on Drug Safety20160

高被引文献

1. 1
   Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practiceExpert Opinion on Drug Safety201964
2. 2
   Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus KinasesExpert Opinion on Drug Safety202044
3. 3
   The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritisExpert Opinion on Drug Safety201911
4. 4
   Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsExpert Opinion on Drug Safety20217
5. 5
   Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variablesTherapeutics and Clinical Risk Management20184

主要发表期刊